Metformin is associated with decreased skin cancer risk in Taiwanese patients with type 2 diabetes - 14/03/18
Abstract |
Background |
Metformin, an antidiabetic drug, is associated with decreased cancer risk, but its effect on skin cancer is unknown.
Objective |
To evaluate skin cancer risk associated with metformin use.
Methods |
In total, 16,237 matched pairs of ever and never metformin users with new-onset type 2 diabetes diagnosed during 1999-2005 were retrospectively enrolled and followed until December 31, 2011, using Taiwan’s National Health Insurance database. Hazard ratios (HRs) were estimated using Cox regression weighted for propensity scores.
Results |
Skin cancer incidence was 45.59 and 83.90 per 100,000 person-years among ever and never users, respectively (HR 0.540, 95% confidence interval [CI] 0.357-0.819). Among ever users, the HRs (95% CIs) for the first (<21.00 months), second (21.00-45.83 months), and third (>45.83 months) cumulative duration tertiles were 0.817 (0.448-1.489), 0.844 (0.504-1.412), and 0.114 (0.036-0.364), respectively, and the HRs (95% CIs) for the first, second, and third cumulative dose tertiles were 1.006 (0.579-1.748), 0.578 (0.317-1.051), and 0.229 (0.099-0.530), respectively. HRs (95% CIs) were 0.523 (0.175-1.562) for melanoma and 0.496 (0.319-0.772) for nonmelanoma skin cancer.
Limitations |
Few patients had skin cancer and information on ultraviolet light exposure and tumor histopathology was lacking.
Conclusion |
Metformin use is associated with a decreased skin cancer risk.
Le texte complet de cet article est disponible en PDF.Key words : diabetes mellitus, metformin, skin cancer, Taiwan
Abbreviations used : HR, ICD-9-CM, NHI, NMSC, PS, UV
Plan
| Funding sources: Supported by the Ministry of Science and Technology (MOST 103-2314-B-002-187-MY3) of Taiwan. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. |
|
| Conflicts of interest: None disclosed. |
|
| Reprints not available from the authors. |
Vol 78 - N° 4
P. 694-700 - avril 2018 Retour au numéro
Article précédent
- Statin use and risk of skin cancer
- Brian M. Lin, Wen-Qing Li, Eunyoung Cho, Gary C. Curhan, Abrar A. Qureshi
- Estimating the cost of skin cancer detection by dermatology providers in a large health care system
- Martha Matsumoto, Aaron Secrest, Alyce Anderson, Melissa I. Saul, Jonhan Ho, John M. Kirkwood, Laura K. Ferris
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?